Screener
AngioDynamics ANGO Sales & Marketing
Sales & Marketing at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: AngioDynamics’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 3:42 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-048138
| Line item | Year ended May 31, 2026 | Year ended May 31, 2025 | Year ended May 31, 2024 |
|---|---|---|---|
| Gross margin | 174,892 | 157,705 | 154,698 |
| Operating expenses | |||
| Research and development | 29,447 | 26,222 | 31,512 |
| Sales and marketing | 113,401 | 103,135 | 102,818 |
| General and administrative | 43,691 | 42,092 | 41,164 |
| Amortization of intangibles | 10,682 | 10,318 | 13,048 |
| Goodwill impairment | — | — | 159,476 |
| Change in fair value of contingent consideration | — | 272 | 432 |
Item 15. Exhibits, Financial Statement Schedules.
FAQ
- What is AngioDynamics's sales & marketing?
- AngioDynamics (ANGO) reported sales & marketing of $31.12M in Q1 2026.
- How has AngioDynamics's sales & marketing changed year-over-year?
- AngioDynamics's sales & marketing increased by 17.7% year-over-year, from $26.44M to $31.12M.
- What is the long-term trend for AngioDynamics's sales & marketing?
- Over 4 years (2022 to 2026), AngioDynamics's sales & marketing has grown at a 4.4% compound annual growth rate (CAGR), from $95.3M to $113.4M.
- What does sales & marketing mean?
- Costs of selling products and services including sales force compensation, commissions, marketing campaigns, trade shows, and customer acquisition expenses.
Ask your AI about AngioDynamics's sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude